The U.S. Department of the Treasury issued new rules that will curb tax-motivated inversions. These rules will affect the proposed Pfizer-Allergan merger and can affect other types of cross-border deals and domestic transactions. Loeb & Loeb partner John F. Settineri is quoted on the likely impacts on the Pfizer-Allergan deal.
Click here to read the article on the Law360 website.